3rd Department of Pediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, GR-54642 Thessaloniki, Greece.
Antimicrob Agents Chemother. 2011 May;55(5):1968-74. doi: 10.1128/AAC.00959-10. Epub 2011 Feb 22.
Biofilm formation complicates the treatment of various infections caused by Candida species. We investigated the effects of simultaneous or sequential combinations of two triazoles, voriconazole (VRC) and posaconazole (PSC), with two echinocandins, anidulafungin (AND) and caspofungin (CAS), against Candida albicans and Candida parapsilosis biofilms in comparison to their planktonic counterparts. Antifungal activity was assessed by the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]2H-tetrazolium-5-carboxanilide (XTT) metabolic assay. Antifungal-agent interactions were analyzed by the Bliss independence model in the simultaneous-treatment studies and by analysis of variance (ANOVA) in the sequential-treatment studies. Against C. albicans planktonic cells, the simultaneous combination of PSC (32 to 128 mg/liter) and CAS (0.008 to 0.25 mg/liter) was synergistic; the combinations of PSC (128 to 1,024 mg/liter) with AND (0.03 to 0.5 mg/liter) and VRC (32 to 512 mg/liter) with AND (0.008 to 0.03 mg/liter) were antagonistic. Against C. parapsilosis planktonic cells, the interaction between VRC (32 to 1,024 mg/liter) and CAS (1 to 16 mg/liter) was antagonistic. All simultaneous antifungal combinations demonstrated indifferent interactions against biofilms of both Candida species. Damage to biofilms of both species increased (P<0.01) in the presence of subinhibitory concentrations of echinocandins (0.008 to 0.064 mg/liter), followed by the addition of PSC (512 mg/liter for C. albicans and 64 to 512 mg/liter for C. parapsilosis) or VRC (256 to 512 mg/liter for C. albicans and 512 mg/liter for C. parapsilosis). Triazole-echinocandin combinations do not appear to produce antagonistic effects against Candida sp. biofilms, while various significant interactions occur with their planktonic counterparts.
生物膜的形成使各种念珠菌引起的感染的治疗变得复杂。我们研究了两种三唑类药物伏立康唑(VRC)和泊沙康唑(PSC)与两种棘白菌素类药物阿尼芬净(AND)和卡泊芬净(CAS)同时或序贯联合应用对白色念珠菌和近平滑念珠菌生物膜的影响,并与浮游细胞进行了比较。抗真菌活性通过 2,3-双[2-甲氧基-4-硝基-5-磺苯基]-2H-四唑-5-羧基苯胺(XTT)代谢测定法进行评估。同时处理研究中采用 Bliss 独立性模型和序贯处理研究中采用方差分析(ANOVA)分析抗真菌药物相互作用。对浮游细胞的白色念珠菌,PSC(32 至 128 mg/L)与 CAS(0.008 至 0.25 mg/L)的同时组合具有协同作用;PSC(128 至 1024 mg/L)与 AND(0.03 至 0.5 mg/L)和 VRC(32 至 512 mg/L)与 AND(0.008 至 0.03 mg/L)的组合具有拮抗作用。对浮游细胞的近平滑念珠菌,VRC(32 至 1024 mg/L)与 CAS(1 至 16 mg/L)之间的相互作用具有拮抗作用。所有同时使用的抗真菌组合对两种念珠菌生物膜均表现出无差异的相互作用。在亚抑菌浓度的棘白菌素(0.008 至 0.064 mg/L)存在下,生物膜的损伤增加(P<0.01),随后加入 PSC(白色念珠菌为 512 mg/L,近平滑念珠菌为 64 至 512 mg/L)或 VRC(白色念珠菌为 256 至 512 mg/L,近平滑念珠菌为 512 mg/L)。三唑类-棘白菌素类药物联合应用似乎不会对念珠菌生物膜产生拮抗作用,而与浮游细胞相比,会产生各种显著的相互作用。